This activity is supported by an educational grant from Sanofi US.
Kenneth Cusi, MD, FACE, FACP
Professor and Chief
Department of Medicine
Division of Endocrinology, Diabetes and Metabolism
University of Florida
This activity is designed to update clinicians on the appropriate use of insulin to optimize therapy in patients with diabetes. The efficacy and safety of newer therapies will be discussed as well as the proper timing of insulin therapy initiation. As part of the activity, the faculty will review treatment guidelines and make practical suggestions on how to overcome barriers to insulin therapy.
This CME activity is intended for endocrinologists, primary care physicians, IM professionals, clinical diabetes educators (CDEs), nurses, physician assistants (PAs) and nurse practitioners (NPs).
Release Date: April 30, 2018
Expiration Date: April 30, 2019
Upon completion of this CME activity, you should be better prepared to:
Articulate clinical strategies for the timely initiation and modification, and intensification of insulin therapy to achieve glycemic control.
Compare clinical data on new insulin formulations and combination insulin/incretin therapies, including pharmacological profiles surrounding efficacy and safety, such as effects on hypoglycemia and nocturnal hypoglycemia and weight gain.
Explain novel strategies to optimize insulin therapy in clinical practice to improve glucose control, reduce risk of weight gain and hypoglycemia, and increase patient acceptance and adherence
Utilize a collaborative team-based approach to patient care that safely appropriately and effectively transition patients to concentrated insulin and insulin combinations.
Physicians' Education Resource®, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians, and is a provider approved by the California Board of Registered Nursing (CBRN).
Physicians' Education Resource®, LLC designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™
and for 1 contact hour for nurses. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Kenneth Cusi, MD, FACE, FACP
– Dr Cusi has conducted grant/research support for Janssen Pharmaceuticals, Novartis, Cirius Therapeutics, Novo Nordisk, and Zydus Pharmceuticals. Dr Cusi has completed cosultant work for Bristol-Myers Squibb, Gilead Sciences, Lilly, and Janssen.
The staff of
Physicians' Education Resource®
, LLC have no relevant financial relationships with commercial interests.
This activity may or may not discuss investigational, unapproved, or off-label uses of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this CME activity is for continuing medical education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to the diagnostic, treatment, and management options for a specific patient’s medical condition.
The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of Physicians’ Education Resource®
, LLC, or any of the companies that provided commercial support for this activity.